Indivior Pharmaceuticals, Inc.
INDV· Nasdaq
INDVIndivior Pharmaceuticals, Inc.
Filed May 1, 2025 · 10-Q · 31 days after period end · 0001625297-25-000030
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $266.00M | $284.00M |
| Net Income | $47.00M | $61.00M |
| EPS Diluted | $0.38 | $0.45 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Indivior Pharmaceuticals, Inc. · CIK 1625297 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 1, 2025 · 31 d after period end
